Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review.

Date publication

février 2016

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie

Tous les auteurs :
Fiteni F, Anota A, Westeel V, Bonnetain F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26892541

Résumé

Health-related quality of life (HRQoL) is recognized as a component endpoint for cancer therapy approvals. The aim of this review was to evaluate the methodology of HRQoL analysis and reporting in phase III clinical trials of first-line chemotherapy in advanced non-small cell lung cancers (NSCLC).

Mots clés

Carcinoma, Non-Small-Cell Lung, drug therapy, Clinical Trials, Phase III as Topic, Humans, Linear Models, Lung Neoplasms, drug therapy, Quality of Life, Surveys and Questionnaires

Référence

BMC Cancer. 2016 Feb;16:122